- Shopping Bag ( 0 items )
From The CriticsReviewer: Michael Joel Schrift, D.O., M.A.(University of Illinois at Chicago College of Medicine)
Description: "This valuable book covers the landmark CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) trial, "the largest, longest and most comprehensive study of schizophrenia to date." The conclusions for psychiatry and for the treatment of schizophrenia are sad and disappointing: after all these years, the newer and expensive antipsychotic medications are not significantly better than the older and less expensive conventional antipsychotic agents. This book details the design, statistical analyses, and implications of this study on clinicians and researchers. Written and edited by the nationally recognized clinician-researchers involved in the study, this book is a welcome addition to the field. "
Purpose: The purpose is to provide the details as well as the implications and ramifications of the findings of this landmark study.
Audience: The intended audience includes researchers, clinicians, policymakers, and hopefully pharmaceutical corporation CEOs.
Features: All of the important aspects of the study are discussed in detail, including the study design and protocol development process, statistical considerations, effectiveness and efficacy, cost-effectiveness and cost-benefit analysis, psychosocial functioning assessments, assessment of neurocognition, family outcomes, extrapyramidal side effects, metabolic side effects, substance use in schizophrenia, violence in schizophrenia, genetic investigations, human subject considerations, population pharmacokinetics, and implications for practice and policy. Each chapter concludes with relevant and timely citations of the scientific literature.
Assessment: "This important and timely book contains the "definitive archival results" of this landmark study. At least for me, in terms of the countless me-too drugs designed by the pharmaceutical industry, this book and study demonstrate that the emperor has no clothes. Unfortunately for psychiatry, the efficacy of almost all of our treatments has not improved for all the illnesses that we treat. The side effects and costs have changed, however. "